HCAR1通过乳酸介导的AMPK-SCD1信号和脂质代谢调节胃癌铁下垂。

IF 4.1 4区 医学 Q3 ONCOLOGY
Oncology Research Pub Date : 2025-09-26 eCollection Date: 2025-01-01 DOI:10.32604/or.2025.067247
Songhua Bei, Qianqian Guo, Xinglei Wu, Fan Li, Yaya Xie, Xiaohong Zhang, Li Feng, Xingxing Zhang
{"title":"HCAR1通过乳酸介导的AMPK-SCD1信号和脂质代谢调节胃癌铁下垂。","authors":"Songhua Bei, Qianqian Guo, Xinglei Wu, Fan Li, Yaya Xie, Xiaohong Zhang, Li Feng, Xingxing Zhang","doi":"10.32604/or.2025.067247","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Ferroptosis is a type of regulated cell death characterized by iron-dependent lipid peroxidation, which has been linked to tumor progression and therapeutic resistance. However, the contribution of lactate metabolism and its receptor, hydroxycarboxylic acid receptor 1 (HCAR1), in ferroptosis regulation in gastric cancer (GC) remains poorly understood. Focusing specifically on its effects on cell proliferation, ferroptosis regulation, and the disruption of lactate-mediated metabolic pathways, the study aimed to clarify the role of HCAR1 in GC progression.</p><p><strong>Methods: </strong>Bioinformatics analysis identified prognostic genes associated with ferroptosis in GC. Receiver operating characteristic (ROC) curves were generated to assess the diagnostic potential of the predictive genes. The biological role of HCAR1 was investigated through gain and loss-of-function experiments in GC cell lines, followed by assessments of cell viability, oxidative stress indicators, gene/protein expression, and ferroptosis sensitivity under lactate stimulation or HCAR1 modulation.</p><p><strong>Results: </strong>HCAR1 was significantly upregulated in GC tissues and linked to poor patient outcomes. Silencing HCAR1 inhibited GC cell growth and induced ferroptosis, as shown by increased levels of reactive oxygen species (ROS) and malondialdehyde (MDA), along with decreased expression of solute carrier family 7 member 11 (SLC7A11) and glutathione peroxidase 4 (GPX4). Conversely, HCAR1 overexpression or exposure to extracellular lactate inhibited ferroptosis and activated antioxidant defenses. Mechanistically, lactate activation of HCAR1 increases ATP levels, which in turn inactivates AMP-activated protein kinase (AMPK). It also upregulates stearoyl-CoA desaturase 1 (SCD1) through the sterol regulatory element binding protein 1 (SREBP1) signaling pathway. Blocking HCAR1 reversed these effects and restored ferroptosis sensitivity.</p><p><strong>Conclusion: </strong>HCAR1 mediates lactate-driven ferroptosis resistance in GC through the AMPK-SCD1 signaling pathway. Targeting the HCAR1-lactate axis may offer a promising strategy for overcoming metabolic adaptation and improving GC treatment outcomes.</p>","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"33 10","pages":"3101-3125"},"PeriodicalIF":4.1000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12494118/pdf/","citationCount":"0","resultStr":"{\"title\":\"<i>HCAR1</i> Modulates Ferroptosis in Gastric Cancer via Lactate-Mediated AMPK-SCD1 Signaling and Lipid Metabolism.\",\"authors\":\"Songhua Bei, Qianqian Guo, Xinglei Wu, Fan Li, Yaya Xie, Xiaohong Zhang, Li Feng, Xingxing Zhang\",\"doi\":\"10.32604/or.2025.067247\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Ferroptosis is a type of regulated cell death characterized by iron-dependent lipid peroxidation, which has been linked to tumor progression and therapeutic resistance. However, the contribution of lactate metabolism and its receptor, hydroxycarboxylic acid receptor 1 (HCAR1), in ferroptosis regulation in gastric cancer (GC) remains poorly understood. Focusing specifically on its effects on cell proliferation, ferroptosis regulation, and the disruption of lactate-mediated metabolic pathways, the study aimed to clarify the role of HCAR1 in GC progression.</p><p><strong>Methods: </strong>Bioinformatics analysis identified prognostic genes associated with ferroptosis in GC. Receiver operating characteristic (ROC) curves were generated to assess the diagnostic potential of the predictive genes. The biological role of HCAR1 was investigated through gain and loss-of-function experiments in GC cell lines, followed by assessments of cell viability, oxidative stress indicators, gene/protein expression, and ferroptosis sensitivity under lactate stimulation or HCAR1 modulation.</p><p><strong>Results: </strong>HCAR1 was significantly upregulated in GC tissues and linked to poor patient outcomes. Silencing HCAR1 inhibited GC cell growth and induced ferroptosis, as shown by increased levels of reactive oxygen species (ROS) and malondialdehyde (MDA), along with decreased expression of solute carrier family 7 member 11 (SLC7A11) and glutathione peroxidase 4 (GPX4). Conversely, HCAR1 overexpression or exposure to extracellular lactate inhibited ferroptosis and activated antioxidant defenses. Mechanistically, lactate activation of HCAR1 increases ATP levels, which in turn inactivates AMP-activated protein kinase (AMPK). It also upregulates stearoyl-CoA desaturase 1 (SCD1) through the sterol regulatory element binding protein 1 (SREBP1) signaling pathway. Blocking HCAR1 reversed these effects and restored ferroptosis sensitivity.</p><p><strong>Conclusion: </strong>HCAR1 mediates lactate-driven ferroptosis resistance in GC through the AMPK-SCD1 signaling pathway. Targeting the HCAR1-lactate axis may offer a promising strategy for overcoming metabolic adaptation and improving GC treatment outcomes.</p>\",\"PeriodicalId\":19537,\"journal\":{\"name\":\"Oncology Research\",\"volume\":\"33 10\",\"pages\":\"3101-3125\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2025-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12494118/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.32604/or.2025.067247\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32604/or.2025.067247","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:铁凋亡是一种以铁依赖性脂质过氧化为特征的调节细胞死亡,与肿瘤进展和治疗耐药性有关。然而,乳酸代谢及其受体羟基羧酸受体1 (HCAR1)在胃癌(GC)中铁下垂调节中的作用仍然知之甚少。该研究特别关注其对细胞增殖、铁凋亡调节和乳酸介导的代谢途径的破坏的影响,旨在阐明HCAR1在GC进展中的作用。方法:通过生物信息学分析确定与胃癌铁下垂相关的预后基因。生成受试者工作特征(ROC)曲线,评估预测基因的诊断潜力。通过GC细胞系的功能增益和功能丧失实验,研究了HCAR1的生物学作用,随后评估了细胞活力、氧化应激指标、基因/蛋白表达以及乳酸刺激或HCAR1调节下的铁中毒敏感性。结果:HCAR1在GC组织中显著上调,并与患者预后不良有关。沉默HCAR1抑制GC细胞生长并诱导铁凋亡,结果显示活性氧(ROS)和丙二醛(MDA)水平升高,溶质载体家族7成员11 (SLC7A11)和谷胱甘肽过氧化物酶4 (GPX4)表达降低。相反,HCAR1过表达或暴露于细胞外乳酸会抑制铁下垂并激活抗氧化防御。从机制上讲,乳酸激活HCAR1会增加ATP水平,进而使amp活化的蛋白激酶(AMPK)失活。它还通过固醇调节元件结合蛋白1 (SREBP1)信号通路上调硬脂酰辅酶a去饱和酶1 (SCD1)。阻断HCAR1逆转了这些作用,恢复了铁下垂的敏感性。结论:HCAR1通过AMPK-SCD1信号通路介导乳酸驱动的胃癌铁凋亡抵抗。靶向hcar1 -乳酸轴可能为克服代谢适应和改善GC治疗结果提供了一种有希望的策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
HCAR1 Modulates Ferroptosis in Gastric Cancer via Lactate-Mediated AMPK-SCD1 Signaling and Lipid Metabolism.

Background: Ferroptosis is a type of regulated cell death characterized by iron-dependent lipid peroxidation, which has been linked to tumor progression and therapeutic resistance. However, the contribution of lactate metabolism and its receptor, hydroxycarboxylic acid receptor 1 (HCAR1), in ferroptosis regulation in gastric cancer (GC) remains poorly understood. Focusing specifically on its effects on cell proliferation, ferroptosis regulation, and the disruption of lactate-mediated metabolic pathways, the study aimed to clarify the role of HCAR1 in GC progression.

Methods: Bioinformatics analysis identified prognostic genes associated with ferroptosis in GC. Receiver operating characteristic (ROC) curves were generated to assess the diagnostic potential of the predictive genes. The biological role of HCAR1 was investigated through gain and loss-of-function experiments in GC cell lines, followed by assessments of cell viability, oxidative stress indicators, gene/protein expression, and ferroptosis sensitivity under lactate stimulation or HCAR1 modulation.

Results: HCAR1 was significantly upregulated in GC tissues and linked to poor patient outcomes. Silencing HCAR1 inhibited GC cell growth and induced ferroptosis, as shown by increased levels of reactive oxygen species (ROS) and malondialdehyde (MDA), along with decreased expression of solute carrier family 7 member 11 (SLC7A11) and glutathione peroxidase 4 (GPX4). Conversely, HCAR1 overexpression or exposure to extracellular lactate inhibited ferroptosis and activated antioxidant defenses. Mechanistically, lactate activation of HCAR1 increases ATP levels, which in turn inactivates AMP-activated protein kinase (AMPK). It also upregulates stearoyl-CoA desaturase 1 (SCD1) through the sterol regulatory element binding protein 1 (SREBP1) signaling pathway. Blocking HCAR1 reversed these effects and restored ferroptosis sensitivity.

Conclusion: HCAR1 mediates lactate-driven ferroptosis resistance in GC through the AMPK-SCD1 signaling pathway. Targeting the HCAR1-lactate axis may offer a promising strategy for overcoming metabolic adaptation and improving GC treatment outcomes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Oncology Research
Oncology Research 医学-肿瘤学
CiteScore
4.40
自引率
0.00%
发文量
56
审稿时长
3 months
期刊介绍: Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信